Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adial Pharmaceuticals (ADIL) Gains from Investment Securities (2022 - 2024)

Adial Pharmaceuticals' Gains from Investment Securities history spans 3 years, with the latest figure at $205000.0 for Q3 2024.

  • For Q3 2024, Gains from Investment Securities rose 2334.68% year-over-year to $205000.0; the TTM value through Sep 2024 reached $205000.0, up 2334.68%, while the annual FY2023 figure was $6068.0, 96.49% down from the prior year.
  • Gains from Investment Securities for Q3 2024 was $205000.0 at Adial Pharmaceuticals, down from $232812.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $4.3 million in Q1 2023 and bottomed at $3577.0 in Q2 2023.
  • The 3-year median for Gains from Investment Securities is $218906.0 (2024), against an average of $683553.1.
  • The largest annual shift saw Gains from Investment Securities crashed 99.4% in 2023 before it surged 2334.68% in 2024.
  • A 3-year view of Gains from Investment Securities shows it stood at $172676.0 in 2022, then tumbled by 96.49% to $6068.0 in 2023, then surged by 3278.38% to $205000.0 in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Gains from Investment Securities are $205000.0 (Q3 2024), $232812.0 (Q1 2024), and $6068.0 (Q4 2023).